First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors. This is an ASCO Meeting Abstract ...
A randomized, multicenter, open-label, phase 2 study of TRK-950 in combination with ramucirumab and paclitaxel as second-line therapy in patients with CAPRIN-1 positive gastric or gastroesophageal ...
On April 29th, 2024, the U.S. FDA granted full approval for Seagen Inc.'s TIVDAK ® (tisotumab vedotin) targeting tissue factor (TF) for the treatment of patients with recurrent or metastatic cervical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results